188 related articles for article (PubMed ID: 15886318)
1. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
2. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Ditzel Santos D; Ho AW; Tournilhac O; Hatjiharissi E; Leleu X; Xu L; Tassone P; Neri P; Hunter ZR; Chemaly MA; Branagan AR; Manning RJ; Patterson CJ; Moreau AS; Ciccarelli B; Adamia S; Kriangkum J; Kutok JL; Tai YT; Zhang J; Pilarski LM; Anderson KC; Munshi N; Treon SP
Exp Hematol; 2007 Sep; 35(9):1366-75. PubMed ID: 17761288
[TBL] [Abstract][Full Text] [Related]
3. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma with Light Chain Discrepancy between B Lymphocyte Population and Serum Paraprotein.
Kim HJ; Hur M; Kim H; Moon HW; Yun YM; Kim SY; Lee MH
Ann Clin Lab Sci; 2015; 45(5):593-7. PubMed ID: 26586715
[TBL] [Abstract][Full Text] [Related]
5. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
[TBL] [Abstract][Full Text] [Related]
6. Establishment of an animal model for Waldenström's macroglobulinemia.
Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
[TBL] [Abstract][Full Text] [Related]
7. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
8. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.
Barakat FH; Medeiros LJ; Wei EX; Konoplev S; Lin P; Jorgensen JL
Am J Clin Pathol; 2011 Mar; 135(3):365-73. PubMed ID: 21350089
[TBL] [Abstract][Full Text] [Related]
9. The development of a model for the homing of multiple myeloma cells to human bone marrow.
Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
[TBL] [Abstract][Full Text] [Related]
10. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
Wang M; Zhang L; Han X; Yang J; Qian J; Hong S; Lin P; Shi Y; Romaguera J; Kwak LW; Yi Q
Clin Cancer Res; 2008 Apr; 14(7):2154-60. PubMed ID: 18381957
[TBL] [Abstract][Full Text] [Related]
11. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
[TBL] [Abstract][Full Text] [Related]
12. A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Tassone P; Neri P; Carrasco DR; Burger R; Goldmacher VS; Fram R; Munshi V; Shammas MA; Catley L; Jacob GS; Venuta S; Anderson KC; Munshi NC
Blood; 2005 Jul; 106(2):713-6. PubMed ID: 15817674
[TBL] [Abstract][Full Text] [Related]
13. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
15. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
16. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
[TBL] [Abstract][Full Text] [Related]
17. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
18. Waldenström macroglobulinemia.
Ghobrial IM; Witzig TE
Curr Treat Options Oncol; 2004 Jun; 5(3):239-47. PubMed ID: 15115652
[TBL] [Abstract][Full Text] [Related]
19. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
20. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
